Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE SEPSIS DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TECHNIQUES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TECHNIQUES COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS
5.1.2 RISE IN HEALTHCARE EXPENDITURE
5.1.3 GROW IN PREVALENCE OF SEPSIS
5.1.4 RISE IN TECHNOLOGICAL ADVANCEMENTS OF SEPSIS DIAGNOSTIC DEVICES
5.2 RESTRAINTS
5.2.1 HIGH COST OF DIAGNOSIS
5.2.2 LACK OF APPROPRIATE TESTING FOR SEPSIS
5.3 OPPORTUNITIES
5.3.1 DEVELOPMENT OF RAPID DIAGNOSTIC/POINT OF CARE (POC) TECHNIQUES FOR EARLY SEPSIS DIAGNOSIS
5.3.2 EVOLUTION OF NOVEL BIOMARKERS FOR SEPSIS DIAGNOSIS
5.4 CHALLENGES
5.4.1 LACK OF AWARENESS ABOUT SEPSIS
5.4.2 SHORTAGE OF SKILLED HEALTHCARE PROFESSIONALS
6 EUROPE SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES
6.1 OVERVIEW
6.2 IMMUNOASSAY
6.2.1 PROCALCITONIN (PCT)
6.2.2 INTERLEUKIN-6 (IL-6)
6.2.3 C-REACTIVE PROTEIN (CRP)
6.2.4 PENTRAXIN-3 (PTX3)
6.2.5 CALPROTECTIN
6.2.6 OTHERS
6.3 MOLECULAR DIAGNOSTIC
6.4 MICROBIOLOGY
6.5 FLOW CYTOMETRY
7 EUROPE SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE
7.1 OVERVIEW
7.2 LABORATORY TESTING
7.3 POINT OF CARE TESTING
8 EUROPE SEPSIS DIAGNOSTICS MARKET, BY REGION
8.1 EUROPE
8.1.1 OVERVIEW
8.1.2 GERMANY
8.1.3 U.K.
8.1.4 FRANCE
8.1.5 REST OF EUROPE
9 EUROPE SEPSIS DIAGNOSTICS MARKET: COMPANY LANDSCAPE
9.1 COMPANY SHARE ANALYSIS: EUROPE
10 COMPANY PROFILE
10.1 ROCHE DIAGNOSTICS
10.1.1 COMPANY SNAPSHOT
10.1.2 REVENUE ANALYSIS
10.1.3 COMPANY SHARE ANALYSIS
10.1.4 PRODUCT PORTFOLIO
10.1.5 RECENT DEVELOPMENT
10.2 ABBOTT.
10.2.1 COMPANY SNAPSHOT
10.2.2 REVENUE ANALYSIS
10.2.3 COMPANY SHARE ANALYSIS
10.2.4 PRODUCT PORTFOLIO
10.2.5 RECENT DEVELOPMENT
10.2.5.1 PRODUCT LAUNCH
10.3 BIOMERIEUX SA
10.3.1 COMPANY SNAPSHOT
10.3.2 REVENUE ANALYSIS
10.3.3 COMPANY SHARE ANALYSIS
10.3.4 PRODUCT PORTFOLIO
10.3.5 RECENT DEVELOPMENT
10.3.5.1 PRODUCT LAUNCH
10.4 THERMO FISHER SCINETIFIC INC.
10.4.1 COMPANY SNAPSHOT
10.4.2 REVENUE ANALYSIS
10.4.3 COMPANY SHARE ANALYSIS
10.4.4 PRODUCT PORTFOLIO
10.4.5 RECENT DEVELOPMENT
10.4.5.1 Acquisition
10.5 BD
10.5.1 COMPANY SNAPSHOT
10.5.2 REVENUS ANALYSIS
10.5.3 COMPANY SHARE ANALYSIS
10.5.4 PRODUCT PORTFOLIO
10.5.5 RECENT DEVELOPMENT
10.6 SEEGENE INC.
10.6.1 COMPANY SNAPSHOT
10.6.2 REVENUE ANALYSIS
10.6.3 PRODUCT PORTFOLIO
10.6.4 RECENT DEVELOPMENT
10.7 AXIS-SHIELD DIAGNOSTICS LTD.
10.7.1 COMPANY SNAPSHOT
10.7.2 PRODUCT PORTFOLIO
10.7.3 RECENT DEVELOPMENTS
10.8 BECKMAN COULTER, INC.
10.8.1 COMPANY SNAPSHOT
10.8.2 PRODUCT PORTFOLIO
10.8.3 RECENT DEVELOPMENTS
10.9 BRUKER
10.9.1 COMPANY SNAPSHOT
10.9.2 REVENUS ANALYSIS
10.9.3 PRODUCT PORTFOLIO
10.9.4 RECENT DEVELOPMENTS
10.1 CEPHEID
10.10.1 COMPANY SNAPSHOT
10.10.2 REVENUE ANALYSIS
10.10.3 PRODUCT PORTFOLIO
10.10.4 RECENT DEVELOPMENT
10.10.4.1 Program launch
10.11 DIASORIN S.P.A.
10.11.1 COMPANY SNAPSHOT
10.11.2 REVENUE ANALYSIS
10.11.3 PRODUCT PORTFOLIO
10.11.4 RECENT DEVELOPMENT
10.11.4.1 ACQUISITION
10.12 EKF DIAGNOSTICS HOLDINGS PLC
10.12.1 COMPANY SNAPSHOT
10.12.2 REVENUE ANALYSIS
10.12.3 PRODUCT PORTFOLIO
10.12.4 RECENT DEVELOPMENT
10.12.4.1 Acquisition
10.13 IMMUNEXPRESS INC.
10.13.1 COMPANY SNAPSHOT
10.13.2 PRODUCT PORTFOLIO
10.13.3 RECENT DEVELOPMENT
10.13.3.1 PRODUCT LAUNCH
10.14 LUMINEX CORPORATION.
10.14.1 COMPANY SNAPSHOT
10.14.2 PRODUCT PORTFOLIO
10.14.3 RECENT DEVELOPMENT
10.14.3.1 Acquisition
10.15 MERIDIAN BIOSCIENCE
10.15.1 COMPANY SNAPSHOT
10.15.2 REVENUS ANALYSIS
10.15.3 PRODUCT PORTFOLIO
10.15.4 RECENT DEVELOPMENTS
10.16 OMEGA DIAGNOSTICS GROUP PLC
10.16.1 COMPANY SNAPSHOT
10.16.2 REVENUE ANALYSIS
10.16.3 PRODUCT PORTFOLIO
10.16.4 RECENT DEVELOPMENT
10.17 ORTHO CLINICAL DIAGNOSTICS.
10.17.1 COMPANY SNAPSHOT
10.17.2 REVENUE ANALYSIS
10.17.3 PRODUCT PORTFOLIO
10.17.4 RECENT DEVELOPMENT
10.17.4.1 PRODUCT LAUNCH
10.18 T2 BIOSYSTEM, INC.
10.18.1 COMPANY SNAPSHOT
10.18.2 PRODUCT PORTFOLIO
10.18.3 RECENT DEVELOPMENT
10.18.3.1 PRODUCT LAUNCH
10.19 TRINITY BIOTECH
10.19.1 COMPANY SNAPSHOT
10.19.2 REVENUE ANALYSIS
10.19.3 PRODUCT PORTFOLIO
10.19.4 RECENT DEVELOPMENT
10.2 XCTON DAGNOSTICS LIMITED
10.20.1 COMPANY SNAPSHOT
10.20.2 PRODUCT PORTFOLIO
10.20.3 RECENT DEVELOPMENT
11 QUESTIONNAIRE
12 RELATED REPORTS
List of Table
TABLE 1 EUROPE SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 2 EUROPE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)
TABLE 3 EUROPE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 4 EUROPE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 5 EUROPE MOLECULAR DIAGNOSTICS IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)
TABLE 6 EUROPE MICROBIOLOGY IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)
TABLE 7 EUROPE FLOW CYTOMETRY IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)
TABLE 8 EUROPE SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 9 EUROPE LABORATORY TESTING IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)
TABLE 10 EUROPE POINT OF CARE TESTING IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)
TABLE 11 EUROPE SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2019-2029 (USD MILLION)
TABLE 12 EUROPE SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 13 EUROPE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 14 EUROPE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 15 EUROPE SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 16 GERMANY SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 17 GERMANY IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 18 GERMANY IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 19 GERMANY SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 20 U.K. SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 21 U.K. IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 22 U.K. IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 23 U.K. SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 24 FRANCE SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 25 FRANCE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 26 FRANCE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 27 FRANCE SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 28 REST OF EUROPE SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
List of Figure
FIGURE 1 EUROPE SEPSIS DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 EUROPE SEPSIS DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE SEPSIS DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE SEPSIS DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE SEPSIS DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE SEPSIS DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE SEPSIS DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE SEPSIS DIAGNOSTICS MARKET: MARKET TECHNIQUES COVERAGE GRID
FIGURE 9 EUROPE SEPSIS DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE SEPSIS DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE GROWING PREVALENCE OF SEPSIS IS EXPECTED TO DRIVE THE EUROPE SEPSIS DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 TECHNIQUES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE SEPSIS DIAGNOSTICS MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA TO DOMINATE AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE EUROPE SEPSIS DIAGNOSTICS MARKET FROM 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINT, OPPORTUNITIES, AND CHALLENGES FOR THE EUROPE SEPSIS DIAGNOSTICS MARKET
FIGURE 15 EUROPE SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES, 2021
FIGURE 16 EUROPE SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES, 2022-2029 (USD MILLION)
FIGURE 17 EUROPE SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES, CAGR (2022-2029)
FIGURE 18 EUROPE SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES, LIFELINE CURVE
FIGURE 19 EUROPE SEPSIS DIAGNOSTICS MARKET: BY TEST TYPE, 2021
FIGURE 20 EUROPE SEPSIS DIAGNOSTICS MARKET: BY TEST TYPE, 2022-2029 (USD MILLION)
FIGURE 21 EUROPE SEPSIS DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2022-2029)
FIGURE 22 EUROPE SEPSIS DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 23 EUROPE SEPSIS DIAGNOSTICS MARKET: SNAPSHOT (2021)
FIGURE 24 EUROPE SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021)
FIGURE 25 EUROPE SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 26 EUROPE SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 27 EUROPE SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES (2022-2029)
FIGURE 28 EUROPE SEPSIS DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)
